JD HEALTH
06618
XIAOMI-W
01810
MEITUAN-W
03690
BILIBILI-W
09626
KUAISHOU-W
01024
HK Stock MarketDetailed Quotes
06127 JOINN
- 13.980
- +0.420+3.10%
Market Closed Mar 5 16:08 CST
10.48BMarket Cap-13980.00P/E (TTM)
14.200High13.500Low2.08MVolume13.800Open13.560Pre Close28.96MTurnover1.75%Turnover Ratio23.90P/E (Static)749.48MShares16.28052wk High1.18P/B1.66BFloat Cap6.31052wk Low0.18Dividend TTM119.00MShs Float69.700Historical High0.180Dividend LFY5.16%Amplitude6.310Historical Low13.902Avg Price100Lot Size1.29%Div YieldTTM1.29%Div Yield LFY
JOINN News
Joinn Laboratories (06127.HK): As of February 28, a total of 3.2698 million A-shares have been repurchased.
On March 3, Gelonghui reported that Joinn Laboratories (06127.HK) announced that as of February 28, 2025, the company has cumulatively repurchased 3.2698 million A-shares through centralized bidding, accounting for 0.4363% of the total shares as of the announcement date. The maximum repurchase price was 18.15 yuan per share, the minimum repurchase price was 13.20 yuan per share, and the total amount of funds used was 52.992 million yuan (excluding transaction fees).
Trending Industry Today: WUXI BIO Leads Losses In CRO Stocks
Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Trending Stocks Today: MINTH GROUP Surges 28.86%
Hong Kong stocks movement | Most CRO Concept stocks rose, and the Industry is expected to enter a stable growth phase. AI pharmaceutical technology and others are worth paying attention to.
Most CRO Concept stocks rose. As of the time of writing, Joinn Laboratories (06127) increased by 14.89% to 12.5 HKD; TIGERMED (03347) rose by 13.17% to 35.65 HKD; Asymchem Laboratories (06821) went up by 5.75% to 58.85 HKD.
Contract Research Organizations concept stocks showed strong performance in early trading, with TIGERMED (03347) up 8.41%. Institutions indicate that the Industry is expected to enter a stable growth phase this year.
Jinwu Finance | Stocks in the Contract Research Organizations sector opened strong. As of the time of writing, TIGERMED (03347) rose 8.41%, Joinn Laboratories (06127) rose 6.62%, PHARMARON (03759) rose 6.22%, Asymchem Laboratories (06821) rose 4.4%, and WUXI APPTEC (02359) rose 2.81%. On the news front, GTJA released a Research Report stating that after experiencing disturbances from multiple factors such as financing disruption, high base from COVID-19, price war competition, and geopolitical disturbances, the current adjustment is nearing its end. In the medium term, technological innovation and upgrades, along with AI, will assist in the drug discovery phase.
Joinn Laboratories (06127.HK) received an increase in shareholding of 0.0443 million shares from E Fund.
On February 19, according to the latest equity disclosure information from the Stock Exchange, on February 13, 2025, Joinn Laboratories (06127.HK) saw E Fund Management Co., Ltd. increase its shareholding by 0.0443 million shares at an average price of HKD 9.9953 per share, involving approximately HKD 0.4428 million. After this shareholding increase, E Fund Management Co., Ltd.'s latest number of shares held is 5.9725 million shares, with its shareholding ratio rising from 4.98% to 5.02%.
GTJA: The new paradigm reshapes the drug development landscape, and the cycle of inventory reduction for Active Pharmaceutical Ingredient is approaching its end.
The CXO adjustments are nearing completion, and the Industry is moving towards the development stage 2.0; the API destocking cycle is coming to an end, seizing opportunities for industrial transformation.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Joinn Laboratories (603127.SH): A total buyback of 0.4363% of A-shares.
On February 6, Gelonghui reported that Joinn Laboratories (603127.SH) announced that as of January 31, 2025, the company has cumulatively repurchased 3,269,820 A-shares through centralized auction trading, accounting for 0.4363% of the company's total shares on the announcement date, with the highest repurchase price being 18.15 RMB/share, the lowest repurchase price being 13.20 RMB/share, and the total amount of funds used being 52,991,757.40 RMB (excluding transaction costs).
Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) Market Cap up CN¥645m Last Week, Benefiting Both Retail Investors Who Own 41% as Well as Insiders
Joinn Laboratories (China) Warns of Up to 85% Profit Slump in 2024
Beijing Zhaoyan New Drug Research Center Co., Ltd. 2024 Annual Results Forecast
Express News | Joinn Laboratories China Sees Operating Revenue in 2024 RMB1.92 Bln to RMB2.12 Bln
JOINN: PROFIT WARNINGANNOUNCEMENT ON THE ESTIMATED DECREASEIN ANNUAL RESULTS FOR THE YEAR OF 2024
Joinn Laboratories (603127.SH) expects a net income of 58.688 million to 88.032 million yuan in 2024, a year-on-year decrease of 77.8% to 85.2%.
Joinn Laboratories (603127.SH) announced that it expects to achieve revenue of approximately 191 million yuan in 2024, ...
【Brokerage Focus】CITIC SEC指出今年是在底部布局医疗健康产业优秀赛道和头部核心企业的最佳机会.
Golden Owl Finance | CITIC SEC stated that the 43rd J.P. Morgan Healthcare Conference will be held from January 13 to 16, 2025, in San Francisco, USA. As the largest and most content-rich healthcare investment seminar in the industry, it brings together global industry leaders, rapidly growing emerging companies, innovative technology creators, and investment professionals. According to the exchanges disclosed by participating companies, specifically, in the area of Innovative Drugs, the technological iteration and business development around core products/fields remain the growth engines for Pharma; in the CXO and upstream life sciences sector, upstream research and development needs are showing moderate recovery.
JOINN Laboratories Announces Key Meeting Outcomes and Governance Changes
Joinn Laboratories (06127) appointed Luo Xuan and Gu Jingliang as executive Directors.
Joinn Laboratories (06127) announced the following appointments: (i) Ms. Luo Xuan and Mr. Gu Jingliang as Executive Directors;(...
Trending Stocks
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Tech and Internet Stocks, ranked from highest to lowest based on real-time market data.
